Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication
GlaxoSmithKline and Innoviva announced that the EMA's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/ vilanterol ‘FF/UMEC/VI’) in a broader group of patients with moderate to severe COPD. September 21, 2018